CAPRICOR THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
CAPR$8.87-9.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE PERIOD FROM DECEMBER 31, 2022 THROUGH DECEMBER 31, 2024
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · OTHER · · · · · TOTAL | |||||||||||||||||
| · · COMMON STOCK · · ADDITIONAL PAID- · · COMPREHENSIVE · · ACCUMULATED · · STOCKHOLDERS' | |||||||||||||||||
| · SHARES · AMOUNT · IN CAPITAL · INCOME · DEFICIT · EQUITY | |||||||||||||||||
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2022 | 25,241,402 | | $25,241 | | $148,735,420 | | $105,244 | | $(137,079,811) | | $11,786,094 | ||||||
| | | | | | | | | | | | | | | | | | |
| Issuance of common stock, net of fees | 5,813,442 | | 5,813 | | 25,509,536 | | — | | — | | 25,515,349 | ||||||
| | | | | | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | 7,392,396 | | — | | — | | 7,392,396 | ||||||
| | | | | | | | | | | | | | | | | | |
| Stock options exercised | 93,476 | | 94 | | 64,507 | | — | | — | | 64,601 | ||||||
| | | | | | | | | | | | | | | | | | |
| Unrealized gain on marketable securities | — | | — | | — | | 130,569 | | — | | 130,569 | ||||||
| | | | | | | | | | | | | | | | | | |
| Net loss | — | | — | | — | | — | | (22,287,542) | | (22,287,542) | ||||||
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2023 | 31,148,320 | | $31,148 | | $181,701,859 | | $235,813 | | $(159,367,353) | | $22,601,467 | ||||||
| | | | | | | | | | | | | | | | | | |
| Issuance of common stock, net of fees | 14,124,536 | | 14,125 | | 152,307,451 | | — | | — | | 152,321,576 | ||||||
| | | | | | | | | | | | | | | | | | |
| Exercise of common warrants | | 105,782 | | | 106 | | | 144,288 | | | — | | — | | 144,394 | ||
| | | | | | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | 9,765,164 | | — | | — | | 9,765,164 | ||||||
| | | | | | | | | | | | | | | | | | |
| Stock options exercised | | 203,650 | | | 203 | | | 305,576 | | | — | | | — | | | 305,779 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | | |
| Unrealized gain on marketable securities | | — | | | — | | | — | | | 791,142 | | | — | | | 791,142 |
| | | | | | | | | | | | | | | | | | |
| Net loss | — | | — | | — | | — | | (40,467,186) | | (40,467,186) | ||||||
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2024 | 45,582,288 | | $45,582 | | $344,224,338 | | $1,026,955 | | $(199,834,539) | | $145,462,336 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.